Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pulmatrix (PULM) has shared an update.
Pulmatrix, Inc. has announced the successful publication of a study in “Headache: The Journal of Head and Face Pain” on the safety, tolerability, and pharmacokinetics of PUR3100, their dry powder inhalable version of dihydroergotamine, compared to the intravenous form. This promising development could be of interest to investors watching for advancements in the pharmaceutical sector, although the company has stated it will not update or amend the released information unless required by future filings.
Learn more about PULM stock on TipRanks’ Stock Analysis page.
